Regeneron and Sanofi Reports Results of Praluent (alirocumab) in ODYSSEY OUTCOMES study in Patients with MACE events, Presented at AHA 2018

 Regeneron and Sanofi Reports Results of Praluent (alirocumab) in ODYSSEY OUTCOMES study in Patients with MACE events, Presented at AHA 2018

Regeneron and Sanofi Reports Results of Praluent (alirocumab) in ODYSSEY OUTCOMES study in Patients with MACE events, Presented at AHA 2018

Shots:

  • The study involves assessing of Praluent (75mg & 150mg, q2w) vs PBO in patients with MACE events and experienced ACS between 1 to 12 mos. in 18,924 patients for duration of 2.8 years
  • The results included 29% reduction in rates of mortality with LDL-C level 100 mg/dL& reduction in cardiovascular events, with no new safety signals observed
  • Praluent IV inhibitor of PCSK9, jointly developed by Regeneron & Sanofi, using Regeneron’s VelocImmune technology. The above data is submitted under EU & has received a PDUFA date as 28 Apr, 2018 from FDA

Click here to read full press release/ article | Ref: Regeneron | Image: Bam Studio

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post